BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...

September 17, 2025 | News

ProBioGen to Operate GMP Manufacturing Hub at Berlin’s New Gene and Cell Therapy Centre

ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process...

September 17, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...

September 16, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Single-Use Systems Are Rewiring Biopharma Manufacturing

Bioprocess, Unbottled Single-use systems (SUS) have become a transformative force in biopharmaceutical processing, offering an alternative to trad...

September 16, 2025 | Report

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs

Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Cytiva and WhiteLab Genomics Partner to Accelerate AAV Genomic Medicine Development

Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timelin...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Stay Connected